| Literature DB >> 24708643 |
Miriam Ortiz1, Claudia M Witt, Sylvia Binting, Cornelia Helmreich, Josef Hummelsberger, Florian Pfab, Michael Wullinger, Dominik Irnich, Klaus Linde, Bodo Niggemann, Stefan N Willich, Benno Brinkhaus.
Abstract
BACKGROUND: In a large randomised trial in patients with seasonal allergic rhinitis (SAR), acupuncture was superior compared to sham acupuncture and rescue medication. The aim of this paper is to describe the characteristics of the trial's participating physicians and to describe the trial intervention in accordance with the STRICTA (Standards for Reporting Interventions in Controlled Trials of Acupuncture) guidelines, to make details of the trial intervention more transparent to researchers and physicians.Entities:
Mesh:
Year: 2014 PMID: 24708643 PMCID: PMC3983860 DOI: 10.1186/1472-6882-14-128
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Acupuncture points used in the ACUSAR trial
| Basic acupuncture points (obligatory) | L.I. 4; L.I. 11; L.I. 20; EX-HN 3 YINTANG | Bilateral (except YINTANG), all together 7 points |
| Basic acupuncture points (optional) | EX-HN 8 BITONG GB 20 LIV 3 LU 7 ST 36 SP 6 SJ 17 BL 13 | Uni- or bilateral, at least 3 points |
| Additional local acupuncture points (optional) | BL 2 GB 1, 14 EX-HN 5 TAIYANG SI 18, SJ 23 ST 2 Further points | At least 3 points (local and distant additional points) uni- or bilateral |
| Additional distant acupuncture points (optional) | LU 1, 5 ST 44 GB 41, 34, 37 LIV 2 LIV 5 KID 3, 7 BL 12, 20, 23, 26, 40 SP 9 REN 6, 17, 22, 20 SJ 5, 6 Further points | |
| Additional ear acupuncture (optional) | Allergy point Shenmen point Thymus point ACTH point Further points |
ACUSAR trial: treatment in the acupuncture group
| | ||||
|---|---|---|---|---|
| | ||||
| 10.0±1.6 | 10.0±1.6 | 10.0±1.5 | 9.9±1.5 | |
| 23.7±3.6 | 23.2±3.9 | 23.9±3.9 | 23.9±4.0 | |
| | | | | |
| ≤ 15 mm | 675 (59.0) | 47 (48.5) | 57 (59.4) | 57 (61.3) |
| 15 to 21 mm | 521 (45.5) | 49 (50.5) | 43 (44.8) | 40 (43.0) |
| 20 to 30 mm | 11 (1.0) | 3 (3.1) | 1 (1.0) | 1 (1.1) |
| | | | | |
| - ‘Deltoideus’ | 1.130 (98.4) | 97 (100.0) | 94 (97.9) | 91 (97.9) |
| - ‘Upper Arm’ | 1.079 (94.2) | 93 (95.9) | 90 (93.8) | 87 (93.6) |
| - ‘Upper Thigh I’ | 1.037 (90.5) | 87 (89.7) | 87 (90.6) | 84 (90.3) |
| - ‘Upper Thigh II’ | 1.011 (88.2) | 89 (91.8) | 84 (87.5) | 81 (87.1) |
| - ‘Upper Thigh III’ | 1.019 (88.9) | 88 (90.7) | 85 (88.5) | 82 (88.2) |
| - ‘Back I’ | 320 (27.9) | 24 (24.7) | 28 (29.2) | 26 (28.0) |
| - ‘Back II’ | 186 (16.2) | 12 (12.4) | 17 (17.7) | 15 (16.1) |
* More than one answer possible.
Figure 1ACUSAR trial: patients’ flow chart.
ACUSAR trial: characteristics of participating trial physicians and assessment of intervention (n=46)
| Number of acupuncture sessions/centre | 64.5; 48 (12-174) |
| Number of acupuncture and sham acupuncture sessions/centre | 94.3; 72 (12-252) |
| Patients/Centre | 6; 46 (27-69) |
| Age (years) | 47±10; 46 (27-69) |
| Female | 24 (52%) |
| Medical practice prior to study initiation (years) | 20±11; 19 (1-46) |
| Postgraduate specialisation | 31 (67%) |
| Postgraduate education | |
| - In acupuncture | 31 (67%) |
| - In naturopathy | 19 (42%) |
| - In homeopathy | 2 (4%) |
| Acupuncture B diploma (at least 350 hours of training) | 33 (73%) |
| Hours of acupuncture training | 672±462; 500 (140-2550) |
| Teacher of acupuncture in accredited postgraduate courses | 16 (35%) |
| Use of acupuncture prior to study initiation (years) | 14±7; 15 (1-30) |
| Participation in earlier clinical trials | |
| - In general | 34 (74%) |
| - On acupuncture | 24 (52%) |
| - With randomisation | 29 (63%) |
| - With sham or placebo acupuncture | 21 (46%) |
| Membership in professional societies | |
| - In total | 38 (83%) |
| - German Medical Acupuncture Association (DÄGfA) | 16 (35%) |
| - International Society for Chinese Medicine (SMS) | 16 (35%) |
| - German Association for Acupuncture and Neural Therapy (DGfAN) | 4 (9%) |
| - In more than one acupuncture society | 9 (20%) |
| - Others | 10 (22%) |
| Patients treated with acupuncture by trial physicians in the year before the trial: | |
| - In total | 420; 150 (15-5000) |
| - Patients with seasonal allergic rhinitis | 58; 20 (0-550) |
| Therapies used in patients in everyday practice (percentages) | |
| - Acupuncture | 41% (5-100%) |
| - Other Chinese Medicine therapies (e.g. Chinese herbal medicine) | 28% (1-95%) |
| - Other complementary therapies | 23% (1-90%) |
| - Conventional medicine | 41% (2-100%) |
| Chinese diagnosis before treatment | |
| - Always | 24 (52%) |
| - Frequently | 20 (43%) |
| - Rarely | 2 (4%) |
| - Never | 0 |
ACUSAR trial: Chinese medicine syndrome diagnoses (n=422)
| Patients with one CM diagnosis | | 117 (27.7) |
| Patients with two CM diagnoses | | 217 (51.4) |
| Patients with three CM diagnoses | | 88 (20.9) |
| | (n=422 patients) | (n=815 diagnoses) |
| | n (%) | n (%) |
| ‘Wind cold’ | 156 (37.0) | 221 (27.1) |
| ‘Wind heat’ | 155 (36.7) | 238 (29.2) |
| ‘Liver heat’ | 33 (7.8) | 105 (12.9) |
| ‘Chronic heat, yin deficiency’ | 16 (3.8) | 37 (4.5) |
| ‘Chronic heat in the lung’ | 21 (5.0) | 55 (6.7) |
| ‘Lung and spleen qi deficiency’ | 36 (8.5) | 132 (16.2) |
| ‘Yang deficiency in kidneys’ | 5 (1.2) | 27 (3.3) |
| | ||
| ‘Wind cold’ & ‘wind heat in the lung’ | 74 (24.3) | |
| ‘Wind heat’ & ‘lung and spleen qi’ | 38 (12.5) | |
| ‘Wind cold’ & ‘lung and spleen qi’ | 47 (15.4) | |
| ‘Wind heat’ & ‘liver heat’ | 45 (14.8) | |
| Others | 101 (33.1) |
ACUSAR trial: treatment in the acupuncture group
| | ||||
|---|---|---|---|---|
| | ||||
| 15.7±2.5 | 15.7±2.5 | 15.8±2.5 | 15.7±2.7 | |
| 24.4±4.4 | 24.3±4.5 | 24.5±4.6 | 24.6±4.7 | |
| | | | | |
| ≤ 20 mm | 1.784 (72.7) | 156 (72.9) | 151 (73.7) | 147 (73.1) |
| 21 to 30 mm | 2.053 (83.6) | 171 (81.4) | 173 (84.4) | 162 (81.0) |
| 31 to 40 mm | 846 (34.5) | 70 (33.3) | 70 (34.2) | 75 (37.5) |
| ≥ 40 mm | 103 (4.2) | 10 (4.8) | 9 (4.4) | 10 (5.0) |
| | | | | |
| - None | 259 (10.5) | 16 (7.6) | 25 (12.2) | 32 (16.0) |
| - Once | 1.966 (80.1) | 172 (81.9) | 162 (79.0) | 152 (76.0) |
| - More than once | 230 (9.4) | 22 (10.5) | 18 (8.8) | 16 (8.0) |
| | | | | |
| - Easy to elicit | 2.276 (92.9) | 186 (88.6) | 191 (93.2) | 189 (94.5) |
| - Difficult to elicit | 169 (6.9) | 23 (11.0) | 14 (6.9) | 10 (5.0) |
| - Could not be elicited | 10 (0.4) | 1 (0.5) | 0 | 1 (0.5) |
| 12.3±1.9 | 12.3±1.9 | 12.3±1.9 | 12.3±1.9 | |
| | | | | |
| - L.I.4 (right & left) | 2.455 (100) | 210 (100) | 205 (100) | 200 (100) |
| - L.I.11(right & left) | 2.455 (100) | 210 (100) | 205 (100) | 200 (100) |
| - L.I.20 (right & left) | 2.412 (98.2) | 206 (98.1) | 201 (98.1) | 198 (98.5) |
| - Ex-HN3 (Yintang) | 2.432 (99.1) | 208 (99.1) | 203 (99.0) | 199 (99.0) |
| - 7 Points used | 2.378 (96.9) | 205 (97.6) | 198 (96.6) | 194 (97.0) |
| | | | | |
| - GB20 (right & left) | 1.567 (63.8) | 131 (62.4) | 131 (63.9) | 129 (64.5) |
| - LIV3 (right & left) | 1.253 (51.0) | 138 (65.7) | 136 (66.3) | 133 (66.2) |
| - LU7 (right & left) | 1.201 (48.9) | 101 (48.1) | 101 (49.3) | 98 (49.0) |
| - ST36 (right & left) | 1.478 (60.2) | 126 (60.0) | 123 (60.0) | 121 (60.5) |
| - SP6 (right & left) | 1.028 (41.9) | 90 (42.9) | 86 (42.0) | 63 (41.5) |
| - SJ17 (right & left) | 48 (2.0) | 4 (1.9) | 4 (2.0) | 4 (2.0) |
| - BL13 (right & left) | 204 (8.3) | 17 (8.1) | 17 (8.3) | 17 (8.5) |
| - Ex-HN8 (right & left) | 474 (19.3) | 40 (19.1) | 40 (19.5) | 40 (19.4) |
| - Points used >=3 | 2.343 (95.4) | 199 (94.8) | 196 (95.6) | 191 (95.5) |
| 3.5 ± 1.9 | 3.5 ± 1.9 | 3.5 ± 1.9 | 3.5 ± 1.9 | |
| - Local (sessions) | 1.550 (63.1) | 131 (62.4) | 129 (62.9) | 128 (63.7) |
| - Distant (sessions) | 1.991 (81.1) | 169 (80.5) | 167 (81.5) | 162 (81.0) |
| - Points used>=2 | 2.292 (94.5) | 198 (94.3) | 194 (94.6) | 190 (94.5) |
| 967 (39.4) | 82 (39.1) | 81 (39.5) | 78 (39.0) |
*More than one answer possible.
ACUSAR trial: treatment in the sham acupuncture group
| | ||||
|---|---|---|---|---|
| | ||||
| 10.0±1.6 | 10.0±1.6 | 10.0±1.5 | 9.9±1.5 | |
| 23.7±3.6 | 23.2±3.9 | 23.9±3.9 | 23.9±4.0 | |
| | | | | |
| ≤ 15 mm | 675 (59.0) | 47 (48.5) | 57 (59.4) | 57 (61.3) |
| 15 to 21 mm | 521 (45.5) | 49 (50.5) | 43 (44.8) | 40 (43.0) |
| 20 to 30 mm | 11 (1.0) | 3 (3.1) | 1 (1.0) | 1 (1.1) |
| | | | | |
| - ‘Deltoideus’ | 1.130 (98.4) | 97 (100.0) | 94 (97.9) | 91 (97.9) |
| - ‘Upper Arm’ | 1.079 (94.2) | 93 (95.9) | 90 (93.8) | 87 (93.6) |
| - ‘Upper Thigh I’ | 1.037 (90.5) | 87 (89.7) | 87 (90.6) | 84 (90.3) |
| - ‘Upper Thigh II’ | 1.011 (88.2) | 89 (91.8) | 84 (87.5) | 81 (87.1) |
| - ‘Upper Thigh III’ | 1.019 (88.9) | 88 (90.7) | 85 (88.5) | 82 (88.2) |
| - ‘Back I’ | 320 (27.9) | 24 (24.7) | 28 (29.2) | 26 (28.0) |
| - ‘Back II’ | 186 (16.2) | 12 (12.4) | 17 (17.7) | 15 (16.1) |
*More than one answer possible.